The past five years has seen extraordinary successes in immunotherapy for the treatment of cancer, autoimmunity and inflammatory disorders of the skin and gut that underscore the importance of understanding how the immune system works in health and disease. The goal of this competitive renewal application of a 30 year T32 Predoctoral Training Program in Immunology (PTPI) is to train the next generation of leading researchers, critical thinkers and communicators in immunology.
We aim to provide enhanced training opportunities that will prepare trainees with the skills required to make fundamental and sustained contributions to our understanding and application of immunology to human health. Highlights: (1) A trans-disciplinary group of successful basic and clinical researchers in immunology; (2) Training approaches based on autonomy- supportive educational methods that encourage self-directed learning; (3) An emphasis on collaborative research, commitment to the exchange of diverse ideas and perspectives to foster collaboration and seed novel discoveries; (4) A culture of critical thinking that underscores the importance of scientific rigor and reproducibility at all levels of graduate education, scientific development and professional conduct; (5) An individual and Institutional commitment to providing expertise and technology at the cutting-edge of immunological concepts and experimentation; (6) An innovative Broadening Experiences in Scientific Training Program (URBEST) that enables trainees to explore and develop critical skills for effective roles in diverse scientific research careers by providing training in leadership and professionalism and (7) A strong emphasis on scientific communication to peers and the broader public. Our trainees will graduate with broad immunological knowledge and the necessary rigor and critical thinking skills to drive new discoveries combined with the ?soft skills? essential to apply and effectively communicate this knowledge in a variety of research careers in academic institutions, government agencies and industry. New initiatives: (1) 14 additional faculty mentors, providing new research expertise in basic and translational immunology research; in particular, in the fields of cancer immunology, neuroimmunology and innate immunity; (2) Student-initiated leadership and professional development opportunities incorporated at multiple levels; (3) Enhanced networking opportunities for trainees including ?breakfast brainstorming? sessions with invited speakers and a student-led Regional Immunology Trainees Day to exchange ideas with other T32s in the region; (4) Science communication training through unique programs established at the UR and opportunities to build content and connect with the general public through the local Public Broadcasting affiliate, WXXI and (5) External program evaluation by Dr Erin Dolan, U. Georgia Professor and experienced evaluator, tailored to documenting the effectiveness of the program, especially the new and unique elements.

Public Health Relevance

The goal of this competitive renewal application of a 30 year T32 Predoctoral Training Program in Immunology is to train the next generation of leading researchers, critical thinkers and communicators in immunology. Our focus on pre-doctoral training in immunology within a trans-disciplinary and highly collaborative research environment will position our trainees to make important basic research contributions to seed the next generation of immune-therapeutics to improve human health.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Institutional National Research Service Award (T32)
Project #
5T32AI007285-32
Application #
9763404
Study Section
Allergy, Immunology, and Transplantation Research Committee (AITC)
Program Officer
Gondre-Lewis, Timothy A
Project Start
1986-09-30
Project End
2023-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
32
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Rochester
Department
Microbiology/Immun/Virology
Type
School of Medicine & Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Boule, Lisbeth A; Burke, Catherine G; Jin, Guang-Bi et al. (2018) Aryl hydrocarbon receptor signaling modulates antiviral immune responses: ligand metabolism rather than chemical source is the stronger predictor of outcome. Sci Rep 8:1826
Cameron, Scott J; Mix, Doran S; Ture, Sara K et al. (2018) Hypoxia and Ischemia Promote a Maladaptive Platelet Phenotype. Arterioscler Thromb Vasc Biol 38:1594-1606
Richards, Katherine A; DiPiazza, Anthony T; Rattan, Ajitanuj et al. (2018) Diverse Epitope Specificity, Immunodominance Hierarchy, and Functional Avidity of Effector CD4 T Cells Established During Priming Is Maintained in Lung After Influenza A Virus Infection. Front Immunol 9:655
DiPiazza, Anthony; Laniewski, Nathan; Rattan, Ajitanuj et al. (2018) CD4 T Cell Epitope Specificity and Cytokine Potential Are Preserved as Cells Transition from the Lung Vasculature to Lung Tissue following Influenza Virus Infection. J Virol 92:
Simpson, Sydney; Fiches, Guillaume; Jean, Maxime J et al. (2018) Inhibition of Tip60 Reduces Lytic and Latent Gene Expression of Kaposi's Sarcoma-Associated Herpes Virus (KSHV) and Proliferation of KSHV-Infected Tumor Cells. Front Microbiol 9:788
DiPiazza, Anthony; Richards, Katherine; Poulton, Nicholas et al. (2017) Avian and Human Seasonal Influenza Hemagglutinin Proteins Elicit CD4 T Cell Responses That Are Comparable in Epitope Abundance and Diversity. Clin Vaccine Immunol 24:
Murphy, Patrick S; Wang, Jing; Bhagwat, Samir P et al. (2017) CD73 regulates anti-inflammatory signaling between apoptotic cells and endotoxin-conditioned tissue macrophages. Cell Death Differ 24:559-570
DiPiazza, Anthony; Nogales, Aitor; Poulton, Nicholas et al. (2017) Pandemic 2009 H1N1 Influenza Venus reporter virus reveals broad diversity of MHC class II-positive antigen-bearing cells following infection in vivo. Sci Rep 7:10857
Hayashi, Tsuyoshi; Jean, Maxime; Huang, Huachao et al. (2017) Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription. Antiviral Res 146:76-85
Jean, Maxime J; Hayashi, Tsuyoshi; Huang, Huachao et al. (2017) Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation. Front Microbiol 8:2007

Showing the most recent 10 out of 151 publications